Portfolio Companies News
September 24, 2018Altimmune Announces $4.9 million Re...
GAITHERSBURG, Md., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced it has entered into purchase agreements with several institutional investors for the purchase in a registered direct offering of 286,633 shares of its... read more
September 24, 2018Altimmune Awarded $2.5 Million in A...
New funding will allow examination of mucosal immune response and additional vaccine characterization GAITHERSBURG, Md., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced that the Biomedical Advanced Research and Dev... read more
September 19, 2018BONESUPPORT highlights significant ...
Lund, Sweden, 08:00 CET, 19 September 2018 Strategic review has led to important initiatives to strengthen BONESUPPORT’s US and European commercial platforms Excellent progress in creating own distributor network in the US. 18 new distributors contracted. 425 highly motiv... read more
September 18, 2018Strongbridge Biopharma plc to Parti...
DUBLIN, Ireland and TREVOSE, Pa., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced the ... read more
September 18, 2018First patient starts treatment with...
Stockholm – 18 September 2018 – Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced that the first patient has started treatment in the company’s Phase II BRIDGE trial designed to study the Pharmacokinetics (PK), safety and efficacy of Ygalo® in combination with dexamethasone... read more
July 24, 2018Q2 2018 General Market Overview
Since the start in 1996, HealthCap funds have invested in 112 portfolio companies.
41 of the portfolio companies have been taken public on nine different markets.
25 of the portfolio companies’ pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 7 companies with a valuation of USD 1 billion or more and 35 companies with a valuation of SEK 1 billion or more.